AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listing of the claims in the application.

1-27. (Canceled)

28. (Currently Amended) A method for distinguishing ~~identifying~~ a leukemia of T cell, B cell, or myeloid lineage in a human subject comprising the steps of:

providing a single assay device comprising a derivatised solid support having an array of immunoglobulin molecules immobilized in discrete regions on the derivatised solid support, wherein the immunoglobulin molecules are specific for the single cell surface marker antigens of CD3, CD4, CD8, CD14, CD19, and CD56;

contacting a biological sample containing leukocytes obtained from a human subject with the assay device;

allowing leukocytes in the biological sample to bind to the immunoglobulin molecules on the solid support via cell surface marker antigens on the leukocytes to form a pattern of binding on an [[~~the~~]] array of discrete regions each being specific for a single cell surface marker presented only once in the array; and

determining the relative scale of the pattern of simultaneous binding with which the cell surface marker antigens CD3, CD4, CD8, CD14, CD19, and CD56 on the leukocyte have bound to the immunoglobulin molecules on the array, wherein the relative scale of the pattern of CD3, CD4, CD8, CD14, CD19, and CD56 binding on the array distinguishes leukemia of T cell, B cell, or myeloid lineage in the subject.

29. (Currently Amended) The method according to claim 28, wherein the derivatised solid support further contains at least one immunoglobulin specific for single cell surface marker antigens of a T cell, B cell, or myeloid lineage selected from the group consisting of CD2, CD5, CD7, CD9, CD10, CD11b, CD11c, CD13, CD15, CD16, CD20, CD21, CD22, CD23, CD24, CD25, CD33, CD34, CD36, CD37, CD38, CD41, CD42a, CD44, CD44v3-10, CD44v6, CD45, CD45RA, CD45RO, CD52, CD57, CD60, CD61, CD64, CD71, CD79a, CD79b, CD80, CD95, CD103, CD117, CD122, CD134, CD138, CD154, Kappa, Lambda, GPA, HLA-DR, KOR, FMC7, Anti-hlg, and Anti-Ig as herein listed in Example 9, Tables 4 to 8 and Figures 7a and 8a.

30. (Currently Amended) The method according to claim 28, wherein the derivatised solid support further contains 39 immunoglobulins specific for single cell surface marker antigens selected from the list in Table 8 ~~group consisting of CD2, CD5, CD7, CD9, CD10, CD11b, CD11c, CD13, CD15, CD16, CD20, CD21, CD22, CD23, CD24, CD25, CD33, CD34, CD36, CD37, CD38, CD41, CD42a, CD44, CD44v3-10, CD44v6, CD45, CD45RA, CD45RO, CD52, CD57, CD60, CD61, CD64, CD71, CD79a, CD79b, CD80, CD95, CD103, CD117, CD122, CD134, CD138, CD154, Kappa, Lambda, GPA, HLA-DR, KOR, FMC7, Anti-hlg, and Anti-Ig~~.

31. (Currently Amended)The method according to claim 28 wherein the derivatised solid support further contains 41 immunoglobulins specific for single cell surface marker antigens selected from the list in Table 4 ~~group consisting of CD2, CD5, CD7, CD9, CD10, CD11b, CD11c, CD13, CD15, CD16, CD20, CD21, CD22, CD23, CD24, CD25, CD33, CD34, CD36, CD37, CD38, CD41, CD42a, CD44, CD44v3-10, CD44v6, CD45, CD45RA, CD45RO, CD52, CD57, CD60, CD61, CD64, CD71, CD79a, CD79b, CD80, CD95, CD103, CD117, CD122, CD134, CD138, CD154, Kappa, Lambda, GPA, HLA-DR, KOR, FMC7, Anti-hlg, and Anti-Ig~~.

32. (Currently Amended) The method according to claim 28, wherein the derivatised solid support further contains 42 immunoglobulins specific for single cell surface marker antigens selected from the list in Table 5, 6, or 7 ~~group consisting of CD2, CD5, CD7, CD9, CD10, CD11b, CD11c, CD13, CD15, CD16, CD20, CD21, CD22, CD23, CD24, CD25, CD33, CD34, CD36, CD37, CD38, CD41, CD42a, CD44, CD44v3-10, CD44v6, CD45, CD45RA, CD45RO, CD52, CD57, CD60, CD61, CD64, CD71, CD79a, CD79b, CD80, CD95, CD103, CD117, CD122, CD134, CD138, CD154, Kappa, Lambda, GPA, HLA-DR, KOR, FMC7, Anti-hlg, and Anti-Ig~~.

33. (Currently Amended) The method according to claim 28, wherein the derivatised solid support further contains 44 immunoglobulins specific for single cell surface marker antigens selected from the list in Figure 7a ~~group consisting of CD2, CD5, CD7, CD9, CD10, CD11b, CD11c, CD13, CD15, CD16, CD20, CD21, CD22, CD23, CD24, CD25, CD33, CD34, CD36, CD37, CD38, CD41, CD42a, CD44, CD44v3-10, CD44v6, CD45, CD45RA, CD45RO, CD52,~~

~~CD57, CD60, CD61, CD64, CD71, CD79a, CD79b, CD80, CD95, CD103, CD117, CD122, CD134, CD138, CD154, Kappa, Lambda, GPA, HLA-DR, KOR, FMC7, Anti-hlg, and Anti-Ig~~.

34. (Currently Amended) The method according to claim 28, wherein the derivatised solid support further contains 52 immunoglobulins specific for single cell surface marker antigens selected from the list in Figure 8a ~~group consisting of CD2, CD5, CD7, CD9, CD10, CD11b, CD11c, CD13, CD15, CD16, CD20, CD21, CD22, CD23, CD24, CD25, CD33, CD34, CD36, CD37, CD38, CD41, CD42a, CD44, CD44v3-10, CD44v6, CD45, CD45RA, CD45RO, CD52, CD57, CD60, CD61, CD64, CD71, CD79a, CD79b, CD80, CD95, CD103, CD117, CD122, CD134, CD138, CD154, Kappa, Lambda, GPA, HLA-DR, KOR, FMC7, Anti-hlg, and Anti-Ig~~.

35. (Currently Amended) The method according to claim 29, wherein the relative pattern of concurrent binding is detected microscopically, biochemically, histochemically or immunologically.

36. (Previously Presented) The method according to claim 35, wherein the relative pattern of binding is detected microscopically.

37. (Previously Presented) The method according to claim 29 wherein the immunoglobulins are monoclonal antibodies.

38. (Previously Presented) The method according to claim 29 wherein the immunoglobulins are polyclonal antibodies.

39. (Previously Presented) The method according to claim 29 further comprising microscopic analysis of cellular morphology of the leukocytes.

40. (Previously Presented)The method according to claim 29 further comprising histochemical, biochemical or immunological analysis.